PercSys is focused on developing and commercializing devices that make endourologic kidney stone procedures easier, less traumatic, and more effective therapeutically. While the company's current devices influence outcomes of minimally invasive procedures performed in the operating room, devices in the pipeline and clinical efforts expand the company's reach into external, and eventually in-office, stone intervention.
The urology device market is estimated at $4.8 billion worldwide and $2.5 billion in the U.S. It is growing at an annual rate of 8-10% driven by the demographics of an aging population, increased demand for non-invasive procedures, and rising obesity rates. Sales of stone removal products are expected to increase proportionately.
Kidney stones are one of the most common disorders of the urinary tract, affecting approximately 5-7% of all women and 7-10% of all men. Formerly a mostly "male disease", the incidence in females has doubled in the last few decades. An estimated five million patients are diagnosed annually worldwide, with a recurrence rate of 50%.
There exist multiple methods of treating kidney and ureteral stones, and PercSys has three commercially released products and a full development pipeline that includes a tool for each procedure. The company's first commercial product, the PercSys Accordion® Stone Management Device, is a sophisticated microcatheter system for facilitating the treatment of kidney stones in the ureter. By offering the first effective anti-retropulsion device for ureteroscopic lithotripsy, as well as the utility of multiple endoscopic stone management tools in a single device, the initial Accordion device simplies fragmentation and removal procedures. A second product for percutaneous lithotripsy, the 15mm Accordion CoAx® Stone Control Device, was released in Q2 2009. The company added a third product, the 10mm Accordion Coax® Stone Control Device, in the third quarter of 2010. This release added the versatility of the CoAx device platform to a device sized for ureteroscopic procedures.
The Accordion /CoAx products were licensed to Takai Hospital Supply in September 2012. Earlier in 2012, the company completed a license agreement for its initial product developed, Cystoglide®, with Solace Therapeutics, a developer of products for stress urinary incontinence.
The company also has identified a portfolio of additional products that have the capability both to significantly improve the current stone treatment options and eventually to supplant the outdated patient management paradigm for stone disease. Through these efforts, PercSys seeks to become a leading developer of commercial urological devices for the management of all kidney/ureteral stones.
Founded in 2003, PercSys is led by an experienced management team with proven expertise in the development and commercialization of medical devices for a broad range of clinical applications. Since our establishment, we have received equity investments from Compass Technology Partners, Montreux Equity Partners, and Shea Ventures, as well as private investors.